Esoform has been acquired by Ecolab
The family owners of Esoform have sold the company to Ecolab for an undisclosed consideration.
Esoform is active in the study, development, production and commercialization of disinfectants, infection prevention and personal care solutions. The company is a leading player in the Italian hospital market with a presence in pharmacies and the mass market.
Ecolab, based in the US, is the global leader in water, hygiene and energy technologies and services that provide and protect clean water, safe food, abundant energy and healthy environments. With this transaction Ecolab plans to expand its healthcare business into Europe, using the Esoform manufacturing plant as the production hub for the region.
Oaklins' team in Italy advised Esoform on the exit strategy and conducted negotiations with potential buyers throughout the transaction. Through a series of bids, the team optimized their proceeds and obtained a remarkable multiple from Ecolab.
Talk to the deal team
Related deals
Afric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn moreBayer AG has entered into a takeover agreement with Cara Care
Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.
Learn more